

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

Claims 1-107. **[Cancelled]** A modified antibody that binds an antigen, said modified antibody comprising a variant human IgG1 Fc region, wherein said variant human IgG1 Fc

Claim 108. **[Previously Presented]** A mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959.

Claim 109. **[Previously Presented]** An antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or antigen-binding fragment thereof.

Claim 110. **[Previously Presented]** The antibody of claim 109 which is a F(ab')<sub>2</sub> fragment.

Claim 111. **[Previously Presented]** The antibody of claim 109 which is a F(ab') fragment.

Claim 112. [Withdrawn] The antibody of claim 109 which is conjugated to a therapeutic agent.

Claim 113. [Withdrawn] The antibody of claim 112, wherein the therapeutic agent is a cytotoxin.

Claim 114. [Currently Amended – Withdrawn] The antibody of claim 113 wherein said cytotoxin is paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, ~~mitomycin~~ mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, ~~a~~ glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, or cyclophosphamide.

Claim 115. [Withdrawn] The antibody of claim 109 comprising at least one modification in the Fc region.

Claims 116-122. [Cancelled]

Claim 123. [Currently Amended] A pharmaceutical composition comprising (i) a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no. PTA-5962, clone 2D11 having ATCC accession no. PTA-5960, and clone 1F2 having ATCC accession no. PTA-5959, or an antigen-binding fragment thereof; and (ii) a pharmaceutically acceptable carrier.

Claim 124. [Cancelled]

Claim 125. [Withdrawn] A method of treating or preventing an IgE-mediated allergic disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of an antibody which is a chimeric or humanized version of the mouse monoclonal antibody produced by a clone selected from the group consisting of clone 1D5 having ATCC accession no. PTA-5958, clone 2E1 having ATCC accession no. PTA-5961, clone 2H9 having ATCC accession no PTA-5962, clone 2D11 having ATCC accession no. PTA- 2960, and clone 1F2 having ATCC accession no. PTA-5959, or an antigen binding fragment thereof.

Claim 126. [Currently Amended -- Withdrawn] The method of claim 125, wherein said IgE-mediated allergic disorder is asthma, allergic rhinitis, a gastro-intestinal allergies allergy, eosinophilia, conjunctivitis, or glomerular nephritis.

Claim 127. [Withdrawn] The method of claim 125, wherein said patient is human.

Claim 128. [Withdrawn] The method of claim 125, wherein said antibody is humanized.

Claim 129. [Withdrawn] The method of claim 125, wherein the antibody is a F(ab')<sub>2</sub> fragment.

Claim 130. [Withdrawn] The method of claim 125, wherein the antibody is a F(ab') fragment.

Claim 131. [Previously Presented] The pharmaceutical composition of claim 123, wherein said antibody is a chimeric version, or antigen-binding fragment thereof.

Claim 132.     **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a humanized version, or antigen-binding fragment thereof.

Claim 133.     **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a  $F(ab')_2$  fragment.

Claim 134.     **[Previously Presented]** The pharmaceutical composition of claim 123, wherein said antibody is a  $F(ab')$  fragment.

Claim 135.     **[Previously Presented]** The antibody of claim 109, wherein said antibody is a chimeric version, or antigen-binding fragment thereof.

Claim 136.     **[Previously Presented]** The antibody of claim 109, wherein said antibody is a humanized version, or antigen-binding fragment thereof.